WO2006002602A1 - Compose d'extraits d'enveloppe et de tiges de fruits de xanthoceras sorbifolia, son procede de preparation et ses utilisations - Google Patents
Compose d'extraits d'enveloppe et de tiges de fruits de xanthoceras sorbifolia, son procede de preparation et ses utilisations Download PDFInfo
- Publication number
- WO2006002602A1 WO2006002602A1 PCT/CN2005/000988 CN2005000988W WO2006002602A1 WO 2006002602 A1 WO2006002602 A1 WO 2006002602A1 CN 2005000988 W CN2005000988 W CN 2005000988W WO 2006002602 A1 WO2006002602 A1 WO 2006002602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- compound
- stalk
- canopy
- extracted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000010903 husk Substances 0.000 title abstract description 17
- 244000248162 Xanthoceras sorbifolium Species 0.000 title abstract description 6
- 235000009240 Xanthoceras sorbifolium Nutrition 0.000 title abstract description 6
- 235000013399 edible fruits Nutrition 0.000 title description 22
- 239000002904 solvent Substances 0.000 claims abstract description 54
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229930182490 saponin Natural products 0.000 claims abstract description 18
- 150000007949 saponins Chemical class 0.000 claims abstract description 18
- 239000012141 concentrate Substances 0.000 claims abstract description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 208000014644 Brain disease Diseases 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000003480 eluent Substances 0.000 claims abstract description 4
- 235000013402 health food Nutrition 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 240000006394 Sorghum bicolor Species 0.000 claims 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 abstract description 15
- 201000011510 cancer Diseases 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract 2
- 238000005406 washing Methods 0.000 abstract 2
- 208000032274 Encephalopathy Diseases 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 230000003595 spectral effect Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 230000005284 excitation Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000002386 leaching Methods 0.000 description 10
- 150000002338 glycosides Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 230000007954 hypoxia Effects 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- -1 triterpenoid saponin compound Chemical class 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241001632409 Aralia elata Species 0.000 description 1
- 235000015888 Aralia elata Nutrition 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000006467 Camellia japonica Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000233633 Phytophthora drechsleri Species 0.000 description 1
- 241000646858 Salix arbusculoides Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000005601 angeloyl group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229930193445 elatoside Natural products 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- XZTNTFPEHWOKNK-UHFFFAOYSA-N sulfanylidenecyanamide Chemical compound S=NC#N XZTNTFPEHWOKNK-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- ⁇ 3 ⁇ 4 (Xantocaas Sobifolia) is a subfamily: 3 ⁇ 43 ⁇ 4 ⁇ Xinjiang, a genus, mainly divided into 3 ⁇ 4ffl Liaoning, the inner point is @» ⁇ , ⁇ , ⁇ , ⁇ », The knot ⁇ 3 ⁇ 4 ⁇ ⁇ long and anti-J3 ⁇ 4l3 ⁇ 4 ⁇ point, currently ⁇ HE ⁇ ⁇ more than 70 million mu.
- the oil contains 14 and does not delete 3 ⁇ 4m for cooking oil.
- the object of the present invention is that a type of surface ⁇ ⁇ ⁇ ⁇ ⁇ m m ⁇ m ⁇ mm mm, and ⁇ ⁇ ⁇ will open a willow 3 ⁇ 4M scare ⁇ 3 ⁇ 4 « art
- the compound is white needle crystal with a melting point of 267-268 ⁇ , a pale red dark spot at 254 nm, a purple color of sulfuric acid, and a positive Mdish reaction.
- the solvent is water, methanol, ethanol, propanol, butanol and z or acetone, and the solvent has a volume concentration of methanol, ethanol, propanol, butanol or acetone of 35% to 85% ;
- the mixture is stirred at intervals, that is, every 10 to 20 minutes, stirring for 1 to 5 minutes, and the leaching temperature is 60 to 10 (TC, the leaching time is 1 to 3 hours.
- the invention extracts a novel compound from the discarded cultivar and stalk of the genus Corolla, and is searched by CA-CS (Chemical Substance Index) and SCIFINDER. The compound has not been reported, and a compound is added to the triterpenoid saponin compound.
- New member animal experiments of the compound show that it has the function of improving brain function, ie promoting memory, reducing cerebral ischemia and hypoxia, and the in vitro cancer cell experiment of the compound shows that it has the effect of inhibiting cancer cells in vitro;
- the invention not only greatly improves the biological development and utilization value of discarded canopy fruit husks and fruit stalks, but also saves valuable natural resources, and is expected to develop a drug for treating brain diseases and anti-tumor and its function in the future medical field.
- the product has a broad application prospect.
- Figure 1 is a flow chart showing the process of extracting a new compound from the canopy and stalk of the present invention. .
- Fig. 2 is a diagram showing the ultraviolet spectrum of the fruit husk glycoside of the present invention (wavelength: 211.6 nm, absorbance of 0.4554, peak height of 0.1920).
- Fig. 3 is a hydrogen chromatogram of the fruit husk glycoside of the present invention. Test conditions: solvent: pyd (solvent: deuterated pyridine), Temp: 25.0.
- Figure 4 is a magnified view of the hydrogen spectrum of the fruit husk glycoside of the present invention.
- Test conditions solvent pyd (solvent: deuterated. pyridine), Temp: 25.0 ° C / 298.1 (temperature: S5.0 ° C / 298.1 K), I NOVA-500 "BMU500" (instrument model), Relax delay : 2.000 Sec (relaxation delay: 2.000 seconds), Pulse: 47.0degrees (pulse excitation: 47.0°), Acq time: 1.892sec (single acquisition time: 1.892 seconds), Width: 7998.4HZ (spectral width: 7998.4 Hz) , 32 repetitions (repeated acquisition 32 times), FT size: 65536 (Fourier transform points: 65536), Total time: 2min 4sec (total time: 2 minutes 4 seconds). ( ⁇ - ⁇ , ⁇ is 3.0 ⁇ 7.0ppm (chemical shift)). '
- Fig. 5 is a second enlarged view of the hydrogen spectrum of the fruit husk.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 298.1 K)), I NOVA-500 "BMU500" (instrument model), Relax delay : 2.000 Sec (relaxation delay: 2.000 seconds), Pulse: 47.0degrees (pulse excitation: 47.0°), Acq time: 1.892sec (single acquisition time: 1.892 seconds), Widtk7998.4HZ (spectral width: 7998.4 Hz), 32 repetitions (repeated acquisition 32 times), FT size: 65536 (Fourier transform points: 65536), Total time: 2min 4sec (total time: 2 minutes 4 seconds). (BMIWOO- 1 !!, ⁇ is 0.4 ⁇ 2.4ppm (chemical shift)).
- Fig. 6 is a carbon spectrum diagram of the fruit husk glycoside of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 29 S.
- Figure 7 is a magnified view of the carbon spectrum of the genus Phyllantrein of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298-.lK (temperature: 25.0 ° C / 298.1 K), I NOVA-500 "BMU500" (instrument model), Relax delay : l .OOOsec (relaxation delay: 1.000 seconds), Pulse: 30.0degre.es (pulse Excitation: 30.0° ), Acq time : 0.600sec (single acquisition time: 0.600 seconds), Width: 31421.8HZ (spectral width: 31421.8 Hz), 8896 repetitions (repeated acquisition 8896 times), Line broadening: 3.5 HZ
- Figure 8 is a second enlarged view of the carbon spectrum of the fruit husk glycoside of the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 298.1 K), I NOVA-500 "BMU500” (instrument model), Relax delay : l.OOOsec (relaxation delay: 1.000 seconds), Pulse: 30.0degrees (pulse excitation: 30.0°), Acq time: 0.600sec (single acquisition time: 0.600 seconds), Width: 31421.8HZ (spectral width: 31421.8 Hz), 8896 repetitions (Repeat 8896 times), Line broadening: 3.5 HZ (line width: 3.5 Hz), FT size: 65536 (Fourier transform points: 65536), Total time: 7hr 19min 20sec (Total time: 7 hours 19 minutes 20 seconds) .
- BMU-500- 13 C, ⁇ is 51
- Figure 9 is a third enlarged view of the carbon spectrum of the fruit husk glycoside of the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 298.1 K), I NOVA-500 "BMU500” (instrument model), Relax delay : l.OOOsec (relaxation delay: 1.000 seconds), Pulse: 30.0degrees (pulse excitation: 30.0°), Acq time: 0.600sec (single acquisition time: 0.600 seconds), Width: 31421.8HZ (if width: 31421.8 Hz), 8896 repetitions (Repeat 8896 times), Line broadening: 3.5 HZ (line width: 3.5 Hz), FT size: 65536 (Fourier transform points: 65536), Total time: 7hr 19min 20sec (Total time: 7 hours 19 minutes 20 seconds) .
- BMU-500- 13 C S is 100 to 155
- Figure 10 is a carbon-hydrogen correlation map of the genus Phyllantrein of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Bruker-ARX-300 (instrument model), TE: 300K (temperature: 300K), Dl: l.OOOOOOOOsec (relaxation delay: 1 .00000000 #), P1 : 9.80 ⁇ sec (pulse excitation: 9.80 microseconds), AQ: 0.1311220 sec (single acquisition time: 0.1311220 seconds), NS: 48 (repeated acquisition 48 times), SWH: 3906.250 HZ (spectral width: 3906.250 Hz), SI : 1024 (Fourier transform points: 1024x) 024).
- solvent pyd (solvent: deuterated pyridine)
- Bruker-ARX-300 instrument model
- TE 300K (temperature: 300K)
- Dl l.OOOOOOOOOOOOsec
- P1 9.80
- Figure 11 is one of the carbon-hydrogen related enlarged maps of the genus Phyllantrein of the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Bruker-ARX-300 (instrument model), TE: 300K (temperature: 300K), D1: l.OOOOOOOOsec (relaxation delay: 1.00000000 seconds) .
- P1 9.80 sec (pulse excitation: 9.80 microseconds)
- AQ 0.1311220 sec (single acquisition time: 0.1311220 seconds)
- NS 48 (repeated acquisition 48 times)
- SI 1 ⁇ 24 (Fourier transform points: 1024x1024).
- FIG. 12 is a second enlarged view of the carbon-hydrogen correlation of the fruit husk glycoside of the present invention.
- Test conditions solvent: pyd (solvent pyridine), Bruker-ARX-300 model), TE: 300K (temperature: 300K), D1: l.OOOOOOOOsec (relaxation delay: 1.00000000 seconds), P1: 9.80 ⁇ sec (pulse excitation: 9.80 microseconds), AQ: 0.1311220 sec (single acquisition time: 0.1311220 seconds), NS: ' (repeated acquisition 48 times), SWH: 3906.250 HZ (spectral width: 3906.250 Hz), SI: 1024 (Fourier transform points: 1024x1024).
- ARX-300 ⁇ is 0.2 to 3.4 ppm
- 13 C-: ⁇ is 5 to 60 ppm).
- Figure 13 is a third enlarged view of the carbon-hydrogen correlation of the genus Phyllantrein of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Bruker-ARX-300 (, instrument model), TE: 300K (temperature: 300K), D1: l.OOOOOOOOsec (relaxation delay: 1.00000000 seconds), PL- 9.80 ⁇ sec (pulse excitation: 9.80 microseconds), AQ: 0.1311220 sec (single acquisition time: 0.1311220 seconds), NS: 48 (repeated acquisition 48 times), SWH: 3906.250 HZ (spectral width: 3906.250 Hz), SI: 1024 (Fourier transform points: 1024x1024).
- solvent pyd (solvent: deuterated pyridine)
- TE 300K
- D1 l.OOOOOOOOOOsec
- PL- 9.80 ⁇ sec pulse excitation: 9.80 microseconds
- AQ 0.131
- Figure 14 is a carbon-hydrogen remote correlation map of the genus Phyllantrein of the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 298.1 K), I NOVA-500 "BMU500" (instrument model), Relax delay: l.OOOsec (relaxation delay: 1.000 seconds), Acq time: 0.206sec (single acquisition time: 0.206 seconds), Width: 4973.9HZ (spectral width: 4973.9 Hz), 2D Width: 30165.9HZ (two-dimensional spectrum width: 30165.9 Hertz), FT size: 2048 x 2048 (Fourier transform points: 2048 x 2048), Total time: 2 r 18min 44sec (total time: 2 hours 18 minutes 44 seconds).
- BMU -500, 3 ⁇ 4-: F 2 is 0.6 to 9 ppm
- 13 C-: ? 1 is 10
- Figure 15 is one of the carbon-hydrogen remote correlation magnification maps of the genus Phyllantrein of the present invention. Test conditions: solvent: pyd
- Figure 16 is a second perspective view of the carbon-hydrogen remote correlation of the genus Phyllantrein of the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Temp: 25.0 ° C / 298.1 K (temperature: 25.0 ° C / 298.1 K), I NOVA-500.
- BMU500 instrument model
- elax delay l.
- Figure 17 is a third perspective view of the carbon-hydrogen remote correlation of the genus Phyllantrein of the present invention.
- Test conditions solvent: py4 (solvent: deuterated pyridine), Temp: 25.0 °C / 298.1K (temperature: 25.0 °C / 298.1K), I NOVA-500 "BMU500" (instrument model), Relax delay: l.
- Figure 18 is a fourth aspect of the carbon-hydrogen remote correlation amplification map of the genus Phyllantrein of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Temp: 25.0 °C / 298.1K (temperature: 25.0 °C / 298.1K), I NOVA-500 "BMU500" (instrument model), elax delay: l. OOOsec.
- Figure 19 is a hydrogen-hydrogen correlation map of the genus Citrus aurantium in the present invention.
- Test conditions solvent pyd (solvent: deuterated pyridine), Bruker-ARX-300 (instrument model), TE: 300K (temperature: 300K), Dl: 1.50000000sec (relaxation delay: 1.50000000 seconds), P1: 9.80 u see (pulse excitation: 9.80 microseconds), AQ: 0.1311220sec (single acquisition time: 0.1311220 seconds), NS: 48 (repeated acquisition 48 times), SWH: 3906.250 HZ (spectral width: 3906.250 Hz), SI: 512 (Fourier transform points: 512 x 512). (ARX-300, ⁇ is 0 ⁇ 10ppm).
- Figure 20 is a hydrogen-hydrogen correlation map of the genus Phyllantrein of the present invention.
- Test conditions solvent: pyd (solvent: deuterated pyridine), Bruker-ARX-300 (instrument model), TE: 300K (temperature: 300K), Dl: 1.50000000sec (relaxation delay: 1.50000000 seconds), P1: 9.80 sec (pulse excitation: 9.80 microseconds), AQ: 0.1311220 sec (single acquisition time: 0.1311220 seconds), NS: 48 (repeated acquisition 48 times), SWH: 3906.250 HZ (spectral width: 3,906.250 Hz), SI: 512 (Fourier transform points: 512x512).
- ARX-300, 5 0.5 ⁇ 7ppm o
- Figure 21-1 is the first-order mass spectrum (MS) of the crown flavonoids. .
- Figure 21-2 is a second-order mass spectrum (MS) of the genus Citrus. detailed description
- the above-obtained target compound, Guanguan was taken for animal experiments.
- mice both male and female, weighing 18-23 g, were divided into two groups.
- the drug-administered group was administered with a dose of 9 mg/kg of the mice, and the control group was given an equal volume of normal saline.
- the two groups of mice were placed in a Y-maze and the experiment was performed.
- the number of false responses before the mouse learned to reach the correct 10 consecutive responses was recorded.
- the number of false responses was more than 30 times, and the results are shown in Table 1:
- mice were trained according to the Y-maze three-arm random method.
- the pre-selected mice with less than 30 false responses before the 10 consecutive correct reactions were used for the experiment.
- the pre-selected mice were randomly divided into two groups after 24 hours of rest, and the scopolamine was injected intraperitoneally. Mg/kg, causing memory impairment in mice.
- the drug-administered group was intraperitoneally injected with guanosine glucoside at a dose of S g/kg, and the control group was intraperitoneally injected with normal saline for 20 minutes after administration.
- the two groups of mice were placed in a Y-maze for the experiment, and the number of error reactions before the 10 consecutive correct responses were recorded.
- Table 2 The experimental results are shown in Table 2:
- the experiment was divided into two batches: each control group and the Wenguan catechin administration group, and the death time was evaluated by three indicators.
- Oral canopy glycosides twice daily, 2mg / time, a total of 6 days.
- Super-mean death time (x p) Calculate the death time (x p) of some animals larger than x c and average them based on the mean death time (x c) of the control group;
- methanol, propanol or acetone may also be used as the leach solvent of the present invention.
- Example 3 The Xanthoceraside extracted in Example 3 was used for in vitro tumor cell experiments. The experimental methods and results are shown in Table 4. Table 4 Screening results of the activity of scutellaria saponins on six types of tumor cells in vitro
- the target compounds extracted in Examples 1, 2, 3 and 4 of the present invention were subjected to structural identification by chemical and spectral analysis methods (including: UV, ID-NMR, 2D-DMR, EI-MS, ESI-MS, etc.). And data attribution: according to its UV, ESI-MS, 1H-NMR, 13 C-NMR, HMQC, HMBC, TOCSY map data (see Figure 2 ⁇ 21 for details), and refer to the literature [l] Chen YJ, Talceda T , Ogihara Y, et al. Studies on the constituents of Xanthoceras sorbifolia Bunge. III. Minor prosapogenins from the fruits of Xanthoceras sorbifolia Bunge. [J].
- the discovery of the new compound adds a new member to the triterpenoid saponin compound, which greatly increases the utilization value of the discarded cultivar and fruit stalk, and is expected to develop treatment in the future medical field.
- New drugs for brain diseases and tumors are also included in the discovery of the new compound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/631,637 US9884884B2 (en) | 2004-07-07 | 2005-07-05 | Compound extracted from husk and fruit stem of xanthoceras sobifolia and its extracting method and use thereof |
US14/750,349 US10160780B2 (en) | 2004-07-07 | 2015-06-25 | Compound extracted from husk and fruit stem of Xanthoceras sobifolia and its extracting method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410020921.0 | 2004-07-07 | ||
CN200410020921 | 2004-07-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/631,637 A-371-Of-International US9884884B2 (en) | 2004-07-07 | 2005-07-05 | Compound extracted from husk and fruit stem of xanthoceras sobifolia and its extracting method and use thereof |
US14/750,349 Continuation US10160780B2 (en) | 2004-07-07 | 2015-06-25 | Compound extracted from husk and fruit stem of Xanthoceras sobifolia and its extracting method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006002602A1 true WO2006002602A1 (fr) | 2006-01-12 |
Family
ID=35782474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/000988 WO2006002602A1 (fr) | 2004-07-07 | 2005-07-05 | Compose d'extraits d'enveloppe et de tiges de fruits de xanthoceras sorbifolia, son procede de preparation et ses utilisations |
Country Status (2)
Country | Link |
---|---|
US (2) | US9884884B2 (zh) |
WO (1) | WO2006002602A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524824B2 (en) * | 2003-09-04 | 2009-04-28 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
US7727561B2 (en) * | 2001-08-31 | 2010-06-01 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
EP1670491B1 (en) * | 2003-10-09 | 2015-07-29 | Pacific Arrow Limited | Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
US7488753B2 (en) | 2003-10-09 | 2009-02-10 | Pacific Arrow Limited | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
US8614197B2 (en) * | 2003-10-09 | 2013-12-24 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
US7514412B2 (en) * | 2003-10-09 | 2009-04-07 | Pacific Arrow Limited | Anticancer biangeloyl saponins |
US8735558B2 (en) * | 2005-02-14 | 2014-05-27 | Pacific Arrow Limited | Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof |
US10213451B2 (en) * | 2004-09-07 | 2019-02-26 | Pacific Arrow Limited | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells |
US9382285B2 (en) | 2004-09-07 | 2016-07-05 | Pacific Arrow Limited | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells |
US8586719B2 (en) * | 2005-04-27 | 2013-11-19 | Pacific Arrow Limited | Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
US20120277308A1 (en) | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
US9499577B2 (en) | 2009-07-16 | 2016-11-22 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
US9434677B2 (en) | 2009-07-16 | 2016-09-06 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
CN102250195B (zh) * | 2011-07-05 | 2012-08-29 | 杨柏珍 | 一种文冠果壳苷的生产方法 |
CN115260143B (zh) * | 2022-08-31 | 2023-06-23 | 河北瑞龙生物科技有限公司 | 从文冠木中提取杨梅素的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1081369A (zh) * | 1992-07-24 | 1994-02-02 | 中国科学院沈阳应用生态研究所 | 以文冠果子提取“提高脑功能”药物的制备方法 |
CN1349820A (zh) * | 2001-10-31 | 2002-05-22 | 杨柏珍 | 文冠果果壳提取物在制备提高脑功能食品和药品中的应用 |
CN1413724A (zh) * | 2001-08-31 | 2003-04-30 | 银泉科技有限公司 | 防治脑病和益智的脑活性作用物质及其制备方法 |
WO2005037200A2 (en) * | 2003-10-09 | 2005-04-28 | Pacific Arrow Limited | Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1052636C (zh) | 1993-03-29 | 2000-05-24 | 中国科学院沈阳应用生态研究所 | 文冠果子的醇提取物在制备治疗智力低下的药物中的应用 |
CN1092992A (zh) | 1993-03-29 | 1994-10-05 | 中国科学院沈阳应用生态研究所 | 提高脑功能的药物及其制备方法 |
US7524824B2 (en) * | 2003-09-04 | 2009-04-28 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
-
2005
- 2005-07-05 WO PCT/CN2005/000988 patent/WO2006002602A1/zh active Application Filing
- 2005-07-05 US US11/631,637 patent/US9884884B2/en active Active - Reinstated
-
2015
- 2015-06-25 US US14/750,349 patent/US10160780B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1081369A (zh) * | 1992-07-24 | 1994-02-02 | 中国科学院沈阳应用生态研究所 | 以文冠果子提取“提高脑功能”药物的制备方法 |
CN1413724A (zh) * | 2001-08-31 | 2003-04-30 | 银泉科技有限公司 | 防治脑病和益智的脑活性作用物质及其制备方法 |
CN1349820A (zh) * | 2001-10-31 | 2002-05-22 | 杨柏珍 | 文冠果果壳提取物在制备提高脑功能食品和药品中的应用 |
WO2005037200A2 (en) * | 2003-10-09 | 2005-04-28 | Pacific Arrow Limited | Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
Non-Patent Citations (1)
Title |
---|
VOUTQUENNE L. ET AL: "Haemolytic acylated triterpenoid saponins from Harpullia austro-caledonica", PHYTOCHEMISTRY, vol. 66, no. 7, April 2005 (2005-04-01), pages 825 - 835, XP004846755 * |
Also Published As
Publication number | Publication date |
---|---|
US20150368285A1 (en) | 2015-12-24 |
US20080058273A1 (en) | 2008-03-06 |
US10160780B2 (en) | 2018-12-25 |
US9884884B2 (en) | 2018-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006002602A1 (fr) | Compose d'extraits d'enveloppe et de tiges de fruits de xanthoceras sorbifolia, son procede de preparation et ses utilisations | |
EP1800685B1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
CN105168235B (zh) | 偏诺皂苷类化合物在制备治疗老年痴呆以及阿尔茨海默病药物中的应用 | |
CN103342729B (zh) | 咖啡酰基取代的五环三萜类衍生物及其用途 | |
CN102212093B (zh) | 黄酮苷类化合物及其制备方法和用途 | |
EA030048B1 (ru) | Фармацевтическая композиция для лечения головной боли, синдрома травматического поражения черепно-мозгового нерва, головокружения и вертиго, раздражения и возбудимости, бессонницы и/или сонливости и способ ее получения | |
CN109575099A (zh) | 达玛烷皂苷元衍生物及其制备方法和应用 | |
CN101899082B (zh) | 三萜皂苷类化合物、用途及制备方法 | |
EP3461486B1 (en) | Pharmaceutical composition for preventing or treating dementia and improving cognitive function, comprising acanthoside b extracted from glasswort | |
KR100205045B1 (ko) | 신규한 트리테르펜 글리코사이드 화합물, 그의 제조방법 및 그를 함유하는 항암제 조성물 | |
CN111018877B (zh) | 一种土木香中倍半萜类衍生物、其制备方法及应用 | |
CN103169696A (zh) | 黄皮有效成分抗神经退行性疾病的用途 | |
Lamidi et al. | Structural and antimalarial studies of saponins from Nauclea diderrichii bark | |
CN111454317A (zh) | 具有抗炎活性的人参二醇型三萜皂苷、三七叶提取物、药物组合物和化妆品组合物 | |
CN102462727A (zh) | 玉郎伞总黄酮及其单体成分在制备抗肿瘤药物中的作用 | |
CN105079011A (zh) | 一种具有抗肿瘤作用的药物的制备和应用 | |
CN103054889A (zh) | Hederagenin-3-O-arabinopyranoside抗肿瘤的应用 | |
US2552896A (en) | Methanol extraction of cascara sagrada bark | |
US20040247698A1 (en) | Erectile Dysfunction Treatment | |
CN101851271A (zh) | 蓝萼丁素衍生物、制备方法及其用途 | |
CN113061153B (zh) | 吲哚苷类化合物、其制备方法及其应用 | |
Rosa et al. | Analge-sic and Anti-Pyretic Activities of the Root Bark of Rutidea Parviflora (Rubiaceae) | |
CN1095669C (zh) | 含原人参二醇组分皂甙的药物组合物,其制备方法及应用 | |
CN110857285B (zh) | 取代吡唑类化合物、其制备方法、药物组合物及用途 | |
CN109265467B (zh) | 一种中药女贞子来源的七环内酯化合物及其作为抗老年痴呆药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11631637 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 11631637 Country of ref document: US |